J&J Pharma Hit By EU Price Cuts, Weaker Euro
This article was originally published in The Pink Sheet Daily
Executive Summary
Hit from EU pricing cuts is estimated at about $200 million in 2010.
You may also be interested in...
At J&J, Q3 Pharma Performance Is Up, Rest of Business Is Down
Analysts were disappointed in J&J's overall results, but the pharma sector performed well, driven by Remicade and new product sales.
At J&J, Q3 Pharma Performance Is Up, Rest of Business Is Down
Analysts were disappointed in J&J's overall results, but the pharma sector performed well, driven by Remicade and new product sales.
U.S. Merck Looks For Developing Country Markets
Merck's second-quarter results demonstrate the risks and rewards of becoming less U.S.-centric. Emerging markets expansion and new product launches outside of the U.S. drove growth, but EU price cuts dampened revenues and profits.